


# Triple therapy: MET+SU+CANA vs. MET+SU+SITA reductions in SBP at 52 (LOCF)<sup>1</sup>



	baseline (mmHg)	n
■ sitagliptin 100mg	130.1	378
■ canagliflozin 300mg	131.2	377

Canagliflozin is not licensed for the treatment of hypertension.

LS: Least-squares, CI: Confidence interval, SE: Standard error, LOCF: Last observation carried forward.

Reference: 1. Schernthaner G et al. Diabetes Care 2013; 36(9): 2508-2515

This slide deck has been developed by Janssen and is intended for a UK healthcare professional audience only.  
PHGB/MEDed/1113/0016(1)a Date of preparation: August 2014